Clinical observation and metabolomics study of the improvement of cardiac and renal function in patients with chronic kidney disease complicated with heart failure by Xinshen Huanshuai Formula
|更新时间:2025-11-25
|
Clinical observation and metabolomics study of the improvement of cardiac and renal function in patients with chronic kidney disease complicated with heart failure by Xinshen Huanshuai Formula
Beijing Journal of Traditional Chinese MedicineVol. 44, Issue 9, Pages: 1099-1105(2025)
LIU Chenxuan,LU Xiaoguang,ZHENG Lihua,et al.Clinical observation and metabolomics study of the improvement of cardiac and renal function in patients with chronic kidney disease complicated with heart failure by Xinshen Huanshuai Formula[J]. Beijing Journal of Traditional Chinese Medicine,2025,44(09):1099-1105.
LIU Chenxuan,LU Xiaoguang,ZHENG Lihua,et al.Clinical observation and metabolomics study of the improvement of cardiac and renal function in patients with chronic kidney disease complicated with heart failure by Xinshen Huanshuai Formula[J]. Beijing Journal of Traditional Chinese Medicine,2025,44(09):1099-1105. DOI: 10.16025/j.1674-1307.2025.09.003.
Clinical observation and metabolomics study of the improvement of cardiac and renal function in patients with chronic kidney disease complicated with heart failure by Xinshen Huanshuai Formula
in improving cardiac and renal function in patients with chronic kidney disease complicated by heart failure (CKD-HF) through a self-controlled study, and to compare baseline metabolomic differences in patients with different renal prognoses using non-targeted metabolomics.
Methods
2
Thirty-six CKD-HF patients who attended the Department of Nephrology at Guang'anmen Hospital, China Academy of Chinese Medical Sciences, from June to December 2023, were enrolled. On the basis of standard integrated Western therapy, all patients received
Xinshen Huanshuai Formula
for 12 weeks. Clinical outcomes were assessed by physicochemical indicators such as estimated glomerular filtration rate (eGFR) and N-terminal pro
-B-type natriuretic peptide (NT-proBNP), traditional Chinese medicine (TCM) syndrome scores, and Minnesota Living with Heart Failure Questionnaire (MLHFQ) scores to provide objective and subjective evaluations. Metabolomic profiling using ultra-high-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS/MS) was performed on baseline serum samples from 16 patients (8 per group) stratified by renal prognosis to analyze metabolic differences.
Result
2
Thirty-three patients completed follow-up. After 12 weeks of treatment with
Xinshen Huanshuai Formula
, eGFR significantly improved (
P
<
0.01), with a total effective response rate of 69.70%. NT-proBNP and MLHFQ scores decreased significantly (
P
<
0.05 and
P
<
0.01, respectively), and TCM syndrome scores also decreased (
P
<
0.01), with a total effective rate of 72.73%. Non-targeted metabolomics analysis identified 37 differential metabolites. Amino acid metabolites, including tryptophan and arginine, as well as lipids such as unsaturated free fatty acids and medium-chain acylcarnitines, were associated with poor CKD-HF prognosis. Pathway enrichment analysis revealed 12 dysregulated pathways, including fatty acid biosynthesis, reflecting the underlying pathophysiological mechanisms of CKD-HF in patients with different renal prognoses.
Conclusion
2
Xinshen Huanshuai Formula
effectively improves cardiac and renal function in CKD-HF patients, delays renal function deterioration, alleviates clinical symptoms, and enhances quality of life. Significant baseline differences in amino acid and lipid metabolism exist between patients with different renal prognoses, with marked enrichment of the fatty acid biosynthesis pathway.
关键词
Keywords
references
Kidney Disease : Improving Global Outcomes (KDIGO) CKD Work Group . KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease [J ] . Kidney Int , 2024 , 105 ( 4S ): 117 - 314 .
Chronic Kidney Disease Prognosis Consortium , MATSUSHITA K , VAN DER VELDE M , et al . Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis [J ] . Lancet , 2010 , 375 ( 9731 ): 2073 - 2081 .
MATSUSHITA K , BALLEW SH , WANG AY , et al . Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease [J ] . Nat Rev Nephrol , 2022 , 18 ( 11 ): 696 - 707 .
RONCO C , HAAPIO M , HOUSE AA , et al . Cardiorenal syndrome [J ] . J Am Coll Cardiol , 2008 ; 52 ( 19 ): 1527 - 1539 .
WANNER C , AMANN K , SHOJI T . The heart and vascular system in dialysis [J ] . Lancet , 2016 , 388 ( 10041 ): 276 - 284 .
ZAKROCKA I , ZAŁUSKA W . Kynurenine pathway in kidney diseases [J ] . Pharmacol Rep , 2022 , 74 ( 1 ): 27 - 39 .
PAWLAK K , MYSLIWIEC M , PAWLAK D . Haemostatic system,biochemical profiles,kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients [J ] . Thromb Res , 2010 ; 125 ( 2 ): e40 - e45 .
PEDERSEN ER , TUSETH N , EUSSEN SJ , et al . Associations of plasma kynurenines with risk of acute myocardial infarction in patients with stable angina pectoris [J ] . Arterioscler Thromb Vasc Biol , 2015 , 35 ( 2 ): 455 - 462 .
LIU JJ , CHING J , WEE HN , et al . Plasma tryptophan-kynurenine pathway metabolites and risk for progression to end-stage kidney disease in patients with type 2 diabetes [J ] . Diabetes Care , 2023 , 46 ( 12 ): 2223 - 2231 .
TAKKAVATAKARN K , PHANNAJIT J , UDOMKARNJANANUN S , et al . Association between indoxyl sulfate and dialysis initiation and cardiac outcomes in chronic kidney disease patients [J ] . Int J Nephrol Renovasc Dis , 2022 , 15 : 115 - 126 .
BARRETO FC , BARRETO DV , LIABEUF S , et al . Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients [J ] . Clin J Am Soc Nephrol , 2009 , 4 ( 10 ): 1551 - 1558 .
HOU H , HORIKAWA M , NARITA Y , et al . Suppression of indoxyl sulfate accumulation reduces renal fibrosis in sulfotransferase 1a1-deficient mice [J ] . Int J Mol Sci , 2023 , 24 ( 14 ): 11329 .
LYU J , CHEN J , WANG M , YAN F . Klotho alleviates indoxyl sulfate-induced heart failure and kidney damage by promoting M2 macrophage polarization [J ] . Aging (Albany NY) , 2020 , 12 ( 10 ): 9139 - 9150 .
KANG HM , AHN SH , CHOI P , et al . Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development [J ] . Nat Med , 2015 , 21 ( 1 ): 37 - 46 .
SZCZUKO M , KACZKAN M , MAŁGORZEWICZ S , et al . The C18:3n6/C22:4n6 ratio is a good lipid marker of chronic kidney disease (CKD) progression [J ] . Lipids Health Dis , 2020 , 19 ( 1 ): 77 .
AFSHINNIA F , RAJENDIRAN TM , SONI T , et al . Impaired β-oxidation and altered complex lipid fatty acid partitioning with advancing CKD [J ] . J Am Soc Nephrol , 2018 , 29 ( 1 ): 295 - 306 .